- Previous Close
0.4050 - Open
0.4100 - Bid 0.4100 x --
- Ask 0.4150 x --
- Day's Range
0.4100 - 0.4150 - 52 Week Range
0.2900 - 0.4500 - Volume
7,848 - Avg. Volume
104,372 - Market Cap (intraday)
55.83M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
13.83 - EPS (TTM)
0.0300 - Earnings Date Feb 12, 2025 - Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 2, 1999
- 1y Target Est
0.90
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
www.microbix.comRecent News: MBX.TO
View MorePerformance Overview: MBX.TO
Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBX.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBX.TO
View MoreValuation Measures
Market Cap
55.83M
Enterprise Value
49.26M
Trailing P/E
15.96
Forward P/E
20.75
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.25
Price/Book (mrq)
1.97
Enterprise Value/Revenue
1.94
Enterprise Value/EBITDA
7.94
Financial Highlights
Profitability and Income Statement
Profit Margin
21.73%
Return on Assets (ttm)
3.82%
Return on Equity (ttm)
20.04%
Revenue (ttm)
23.36M
Net Income Avi to Common (ttm)
5.08M
Diluted EPS (ttm)
0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
12.81M
Total Debt/Equity (mrq)
22.68%
Levered Free Cash Flow (ttm)
-1.48M